ArisGlobal Releases agClinical 3.3

Chicago (ots/PRNewswire) -

Sets New Benchmark for Transparency and Compliance in Clinical
Trial Management

ArisGlobal, a leading provider of integrated, cloud-based software
solutions for life sciences, announces agClinical 3.3, the latest
version of its comprehensive clinical trial management software. This
release further enables life science organizations to confidently and
efficiently meet new compliance and submission requirements, improve
risk-based monitoring and better manage the electronic trial master
file so that compliance is assured and transparency is improved.

(Logo: http://mma.prnewswire.com/media/448785/ArisGlobal_Logo.jpg
)

- Data Sheet: ArisGlobal's agClinical
(http://www.arisglobal.com/clinical-development/lifesphere-ctms/)
- Webinar Replays: How CRO's Can Boost Profits and Productivity
(http://bit.ly/2dp1PEI) | The Value of Unified CTMS/eTMF
(http://www.arisglobal.com/the-value-of-unified-ctms-etmf/)

"We benefit from a collaborative relationship with our customers,
and we have taken their valued, best-practices input and added new
functionality to our already comprehensive solution to position our
customers for success," said David Laky, ArisGlobal's General Manager
and VP, Clinical Development. "We are confident that agClinical 3.3
responds to their need for reducing the labor-intensive aspects of
clinical trial management."

agClinical 3.3 includes:

- Global Trial Submissions: Important new features that support
global trial submissions irrespective of region, country or
regulations in support of Clinical Trial Regulation (EU) No
536/2014 (http://ec.europa.eu/health/human-use/clinical-trials/regu
lation/index_en.htm).
- Enhanced Automation Leads to Increased Efficiency of Clinical
Research Associates (CRAs): Enhanced capabilities to automate the
monitoring process which will increase the efficiency of Clinical
Research Associates (CRAs). Including remote monitoring
enhancements, a new mobile monitoring module, Microsoft Outlook
integration, e-signed confirmation letter, follow-up letter and
workflow based monitoring that publish approved artifacts to eTMF
that automates the entire monitoring process.
- RACT Tool: Risk Assessment Categorization Tool as defined by
TransCelerate. This tool enables organizations to develop and
implement risk mitigation plans by identifying and entering
information for key risk factors resulting in more efficient
operations and the ability to monitor risk through key risk
indicators.
- Improved Document Management: Advanced functionality and usability
improvements to the integrated electronic trial master file (eTMF),
unified within agClinical, driving companies to meet and exceed
document management obligations.
- Portal with Advanced Functionalities: An advanced Investigator and
Site portal that tracks, onboarding, Investigator scoring, key
study metrics, enables document sharing, and tracks payment
milestones and financial obligations.
- Robust Third-Party Integration: Further enhancements to our already
robust third-party integration tools and APIs (application program
interface). The enhanced middleware acts as a Clinical Backend as
a Service (CBaaS) enabling organizations to integrate with their
systems of choice. Our library of connectors already includes a
growing number of EDC (electronic data capture) and document
management systems as well as the ability to connect to our own
market leading products.

"Clinical trials are highly regulated, complex undertakings," said
Sonia Veluchamy, ArisGlobal Managing Director. "agClinical is
recognized by customers and analysts as one of the most
functionally-rich CTMS solutions on the market. This newest version
further solidifies our position as the leader in this splintered
market."

About ArisGlobal

ArisGlobal's cloud-based solutions facilitate global drug
development and regulatory compliance in the life sciences and
healthcare industries across the entire product life cycle including
clinical development, regulatory affairs, safety and
pharmacovigilance and medical communications. Hundreds of drug and
device manufacturers, CROs and regulatory agencies leverage
ArisGlobal's advanced technology solutions spanning regulatory
information management, pharmacovigilance regulatory reporting,
medical information and clinical trial management software to make
better and more informed decisions, facilitate compliance, reduce
risk, and improve operational efficiency. Headquartered in the United
States, ArisGlobal has regional offices in Europe, India and Japan.
For more information, visit arisglobal.com
(http://www.arisglobal.com), or follow ArisGlobal on LinkedIn
(https://www.linkedin.com/company/aris-global) and Twitter
(https://twitter.com/Aris_Global).

Contact: Chad Kurz | +1.609.360.4067 | [e-mail]

ots Originaltext: ArisGlobal
Im Internet recherchierbar: http://www.presseportal.de